View in EDS

BET, SRC, and BCL2 family inhibitors are synergistic drug combinations with PARP inhibitors in ovarian cancer.

Saved in:
Bibliographic Details
Title: BET, SRC, and BCL2 family inhibitors are synergistic drug combinations with PARP inhibitors in ovarian cancer.
Authors: Lui GYL; Human Biology Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USA. Electronic address: glui@fredhutch.org., Shaw R; SEngine Precision Medicine, Seattle, WA, USA; Cure First, Seattle, WA, USA., Schaub FX; SEngine Precision Medicine, Seattle, WA, USA; Cure First, Seattle, WA, USA., Stork IN; Human Biology Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USA., Gurley KE; Human Biology Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USA., Bridgwater C; SEngine Precision Medicine, Seattle, WA, USA., Diaz RL; SEngine Precision Medicine, Seattle, WA, USA., Rosati R; SEngine Precision Medicine, Seattle, WA, USA; Cure First, Seattle, WA, USA., Swan HA; SEngine Precision Medicine, Seattle, WA, USA., Ince TA; Department of Pathology and Laboratory Medicine, Weill Cornell Medicine, New York, NY, USA & New York Presbyterian-Brooklyn Methodist Hospital, Brooklyn, NY, USA., Harding TC; Clovis Oncology, Boulder, CO, USA., Gadi VK; Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USA., Goff BA; Department of Obstetrics & Gynecology, University of Washington, Seattle, WA, USA., Kemp CJ; Human Biology Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USA., Swisher EM; Department of Obstetrics & Gynecology, University of Washington, Seattle, WA, USA., Grandori C; SEngine Precision Medicine, Seattle, WA, USA; Cure First, Seattle, WA, USA. Electronic address: cgrandori@senginemedicine.com.
Source: EBioMedicine [EBioMedicine] 2020 Oct; Vol. 60, pp. 102988. Date of Electronic Publication: 2020 Sep 11.
Publication Type: Journal Article
Journal Info: Publisher: Elsevier B.V Country of Publication: Netherlands NLM ID: 101647039 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 2352-3964 (Electronic) Linking ISSN: 23523964 NLM ISO Abbreviation: EBioMedicine Subsets: MEDLINE
Database: MEDLINE Ultimate
FullText Text:
  Availability: 0
Header DbId: mdl
DbLabel: MEDLINE Ultimate
An: 32927276
AccessLevel: 2
PubType: Academic Journal
PubTypeId: academicJournal
PreciseRelevancyScore: 0
IllustrationInfo
Items – Name: Title
  Label: Title
  Group: Ti
  Data: BET, SRC, and BCL2 family inhibitors are synergistic drug combinations with PARP inhibitors in ovarian cancer.
– Name: Author
  Label: Authors
  Group: Au
  Data: <searchLink fieldCode="AU" term="%22Lui+GYL%22">Lui GYL</searchLink>; Human Biology Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USA. Electronic address: glui@fredhutch.org.<br /><searchLink fieldCode="AU" term="%22Shaw+R%22">Shaw R</searchLink>; SEngine Precision Medicine, Seattle, WA, USA; Cure First, Seattle, WA, USA.<br /><searchLink fieldCode="AU" term="%22Schaub+FX%22">Schaub FX</searchLink>; SEngine Precision Medicine, Seattle, WA, USA; Cure First, Seattle, WA, USA.<br /><searchLink fieldCode="AU" term="%22Stork+IN%22">Stork IN</searchLink>; Human Biology Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USA.<br /><searchLink fieldCode="AU" term="%22Gurley+KE%22">Gurley KE</searchLink>; Human Biology Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USA.<br /><searchLink fieldCode="AU" term="%22Bridgwater+C%22">Bridgwater C</searchLink>; SEngine Precision Medicine, Seattle, WA, USA.<br /><searchLink fieldCode="AU" term="%22Diaz+RL%22">Diaz RL</searchLink>; SEngine Precision Medicine, Seattle, WA, USA.<br /><searchLink fieldCode="AU" term="%22Rosati+R%22">Rosati R</searchLink>; SEngine Precision Medicine, Seattle, WA, USA; Cure First, Seattle, WA, USA.<br /><searchLink fieldCode="AU" term="%22Swan+HA%22">Swan HA</searchLink>; SEngine Precision Medicine, Seattle, WA, USA.<br /><searchLink fieldCode="AU" term="%22Ince+TA%22">Ince TA</searchLink>; Department of Pathology and Laboratory Medicine, Weill Cornell Medicine, New York, NY, USA & New York Presbyterian-Brooklyn Methodist Hospital, Brooklyn, NY, USA.<br /><searchLink fieldCode="AU" term="%22Harding+TC%22">Harding TC</searchLink>; Clovis Oncology, Boulder, CO, USA.<br /><searchLink fieldCode="AU" term="%22Gadi+VK%22">Gadi VK</searchLink>; Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USA.<br /><searchLink fieldCode="AU" term="%22Goff+BA%22">Goff BA</searchLink>; Department of Obstetrics & Gynecology, University of Washington, Seattle, WA, USA.<br /><searchLink fieldCode="AU" term="%22Kemp+CJ%22">Kemp CJ</searchLink>; Human Biology Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USA.<br /><searchLink fieldCode="AU" term="%22Swisher+EM%22">Swisher EM</searchLink>; Department of Obstetrics & Gynecology, University of Washington, Seattle, WA, USA.<br /><searchLink fieldCode="AU" term="%22Grandori+C%22">Grandori C</searchLink>; SEngine Precision Medicine, Seattle, WA, USA; Cure First, Seattle, WA, USA. Electronic address: cgrandori@senginemedicine.com.
– Name: TitleSource
  Label: Source
  Group: Src
  Data: <searchLink fieldCode="JN" term="%22101647039%22">EBioMedicine</searchLink> [EBioMedicine] 2020 Oct; Vol. 60, pp. 102988. <i>Date of Electronic Publication: </i>2020 Sep 11.
– Name: TypePub
  Label: Publication Type
  Group: TypPub
  Data: Journal Article
– Name: TitleSource
  Label: Journal Info
  Group: Src
  Data: <i>Publisher: </i><searchLink fieldCode="PB" term="%22Elsevier+B%2EV%22">Elsevier B.V </searchLink><i>Country of Publication: </i>Netherlands <i>NLM ID: </i>101647039 <i>Publication Model: </i>Print-Electronic <i>Cited Medium: </i>Internet <i>ISSN: </i>2352-3964 (Electronic) <i>Linking ISSN: </i><searchLink fieldCode="IS" term="%2223523964%22">23523964 </searchLink><i>NLM ISO Abbreviation: </i>EBioMedicine <i>Subsets: </i>MEDLINE
PLink https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=mdl&AN=32927276
RecordInfo BibRecord:
  BibEntity:
    Identifiers:
      – Type: doi
        Value: 10.1016/j.ebiom.2020.102988
    Languages:
      – Code: eng
        Text: English
    PhysicalDescription:
      Pagination:
        StartPage: 102988
    Titles:
      – TitleFull: BET, SRC, and BCL2 family inhibitors are synergistic drug combinations with PARP inhibitors in ovarian cancer.
        Type: main
  BibRelationships:
    HasContributorRelationships:
      – PersonEntity:
          Name:
            NameFull: Lui GYL
      – PersonEntity:
          Name:
            NameFull: Shaw R
      – PersonEntity:
          Name:
            NameFull: Schaub FX
      – PersonEntity:
          Name:
            NameFull: Stork IN
      – PersonEntity:
          Name:
            NameFull: Gurley KE
      – PersonEntity:
          Name:
            NameFull: Bridgwater C
      – PersonEntity:
          Name:
            NameFull: Diaz RL
      – PersonEntity:
          Name:
            NameFull: Rosati R
      – PersonEntity:
          Name:
            NameFull: Swan HA
      – PersonEntity:
          Name:
            NameFull: Ince TA
      – PersonEntity:
          Name:
            NameFull: Harding TC
      – PersonEntity:
          Name:
            NameFull: Gadi VK
      – PersonEntity:
          Name:
            NameFull: Goff BA
      – PersonEntity:
          Name:
            NameFull: Kemp CJ
      – PersonEntity:
          Name:
            NameFull: Swisher EM
      – PersonEntity:
          Name:
            NameFull: Grandori C
    IsPartOfRelationships:
      – BibEntity:
          Dates:
            – D: 01
              M: 10
              Text: 2020 Oct
              Type: published
              Y: 2020
          Identifiers:
            – Type: issn-electronic
              Value: 2352-3964
          Numbering:
            – Type: volume
              Value: 60
          Titles:
            – TitleFull: EBioMedicine
              Type: main
ResultId 1